ArticleClinical nuclear medicine2025
Whole-body MRI Versus [ 18 F]FDG PET/CT in Diagnosing and Monitoring Plasmacytomas : A Comparative Study.
Article in Clinical nuclear medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 1 synthesis or guideline pooled it.
- International Myeloma Working Group Recommendations for the Diagnosis and Management of Solitary Plasmacytomas.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2026Guideline
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND/
objectivesCurrent guidelines recommend [ 18 F]FDG PET/CT as the preferred imaging modality for suspected extramedullary bone plasmacytomas, while whole-body magnetic resonance imaging (WB-MRI) is indicated for solitary bone plasmacytomas. Despite these recommendations, the available evidence comparing the diagnostic efficacy of both techniques remains limited. The aim of this study was to compare the diagnostic efficacy of WB-MRI and [ 18 F]FDG PET/CT in the initial evaluation of plasmacytomas.
methodsWe performed a multicenter, observational, and retrospective analysis of patients diagnosed with plasmacytoma who underwent WB-MRI and/or [ 18 F]FDG PET/CT as part of their diagnostic workup. Lesions identified were categorized by anatomic location, and concordance between WB-MRI and [ 18 F]FDG PET/CT findings was assessed. The McNemar test and Pearson χ 2 test were used to compare detection rates between WB-MRI and [ 18 F]FDG PET/CT.
resultsThe study included 73 patients (33 men) recruited between 2012 and 2023, age range 30-94 years (mean 63.4 ± 12.2 y). Of these, 56 patients underwent both diagnostic tests. Diagnoses revealed solitary plasmacytoma in 16 patients, concurrent multiple myeloma (MM) and plasmacytoma in 18 patients, and plasmacytoma in 22 patients with a prior MM history. Out of the 56 plasmacytomas, 40 were osseous and 16 were extramedullary. WB-MRI detected 98.2% of plasmacytomas compared with 83.9% for [ 18 F]FDG PET/CT, with a statistically significant difference of OR 9 (95% CI: 1.2-394.5), P =0.021. Concordance was very high for osseous plasmacytomas but moderate for extramedullary plasmacytomas.
conclusionsThese findings suggest WB-MRI is an alternative to [ 18 F]FDG PET/CT for detecting plasmacytomas. A comprehensive clinical and radiologic assessment is essential for the optimal evaluation of patients with plasmacytoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.